一年不到，芬兰知名IVD原料企业Medix再度出手，收购EastCoast Bio

Medix Biochemica收购了美国EastCoast Bio (“ECB”)业务；ECB为全球IVD生产商提供高质量的抗原、抗体以及阻断剂。本次并购扩充了Medix Biochemica在数个诊断领域的抗体抗原产品线，诸如药物滥用、传染病、动物检测等。ECB团队的加入也将加强Medix Biochemica在北美的商务能力，与此同时，ECB业务也将得益于Medix Biochemica在欧洲和中国强大的本地团队。

Medix Biochemica has acquired the business of EastCoast Bio, a provider of high-quality antigens, antibodies and blocking buffers for the In-Vitro Diagnostic (IVD) manufacturing industry worldwide. The acquisition broadens Medix Biochemica's antibody and antigen offering in several diagnostic areas, including Drugs of Abuse, Infectious Disease and Veterinary testing. Furthermore, the addition of the ECB team further strengthens the commercial presence of Medix Biochemica in North America, while ECB will benefit from Medix Biochemica's strong local commercial presence in Europe and China.

并购完成后，ECB团队及运营将并入Medix Biochemica免疫诊断原料部。ECB创始人兼CFO Clark L McDermith以及总裁Pamela F Williams将继续在Medix Biochemica 免疫诊断原料业务部担任重要职务。

As a result of the transaction, the organization and operations of ECB will be merged with Medix Biochemica's Immunodiagnostic Reagents Business Unit. ECB's founder and CFO Clark L McDermith and President Pamela F Williams will continue with Medix Biochemica's Immunodiagnostic Reagents Business Unit in key roles.

ECB由Clark L McDermith创立于1995年，是全球性IVD行业供应商，主要提供高质量的抗原、抗体、阻断剂以及定制的免疫试剂。ECB尤其以其领先的药物滥用、传染病、以及动物检测相关抗体、抗原、以及鱼来源的阻断剂而知名。ECB总部位于美国缅因州North Berwick市。

Founded in 1995 by Clark L McDermith, ECB is a supplier of high-quality antigens, antibodies, blocking buffers, and specialized immunoassay reagents for the IVD manufacturing industry worldwide. The company is particularly well known for its leading portfolio of Drugs of Abuse, Infectious Disease and Veterinary antibodies and antigens as well as for its Fish Blocking products. ECB is headquartered in North Berwick, Maine.

“与Clark及Pam领导下的ECB建立伙伴关系令人兴奋，他们已经推出了很广的产品线、建立了高素质的团队，并有极好的财务表现。本次并购体现了Medix Biochemica的战略，即进行IVD行业供应链整合、让我们客户的供应链更强大。我们的长期目标是成为IVD试剂生产商的首选关键原料供应商。这一动作将大大扩充我们的高品质IVD原料产品线，提高我们在药物滥用及传染病检测领域的原料供应能力。而且，ECB的加入、结合前不久对同为美国公司的Lee Bioslutions的收购，还将进一步强化我们在美国这一战略性市场的本地服务能力”，Medix Biochemica首席执行官Steve Ferguson如此说。

“We are excited about entering into this partnership with ECB which, under the leadership of Clark and Pam, has developed a broad product portfolio, built a highly competent team and achieved excellent financial results. The acquisition demonstrates Medix Biochemica’s strategy to consolidate the IVD supply chain and enhance supply chain visibility for our customers. Our long-term aim is to become the #1 supplier of critical raw materials for IVD test manufacturers. This move broadens our high-quality product portfolio of IVD raw materials and expands our capability into Drugs of Abuse and Infectious Disease testing. On top of this, ECB further strengthens our local presence in the strategically important U.S. market, building on our recent acquisition of Lee Biosolutions in the country”, says Steve Ferguson, CEO of Medix Biochemica.

“ECB业务连年持续增长，Medix Biochemica是IVD行业公认的单克隆抗体原料的领先供应商，产能惊人，在欧洲和中国都有出众的商务网络，与Medix Biochemica合并对我们的业务是件大好事，对我们的同事来说也很棒，对我们的客户来说更是天作之合”，ECB的创始人兼首席财务官 Clark L McDermith说。

“ ECB has consistently grown year on year and coming together with Medix Biochemica who are recognized as pioneers in monoclonal antibodies with significant product capability and distribution in Europe and China, is good for our business, good for our staff and above all, great for our customers”, says Clark L McDermith, founder and CFO of ECB.